Patent ID: RE41226

Claim:
A compound of formula (I) wherein: X + is P + (R 1 ,R 2 ,R 3 ), wherein R 1 ,R 2 ,R 3 , being the same or different, are selected in the group consisting of hydrogen, a C 1 -C 9 straight or branched alkyl group, —CH═NH(NH 2 ), —NH 2 , and —OH; or one or more R 1 , R 2 and R 3 , together with the phosphorus atom which they are linked to, form a saturated or unsaturated, monocyclic or bicyclic heterocyclic system; with the proviso that at least one of the R 1 , R 2 and R 3 is different from hydrogen; Z is selected from: —OR 4 , —OCOOR 4 , —OCONHR 4 , —OCSNHR 4 , —OCSOR 4 , —NHR 4 , —NHCOR 4 , —NHCSR 4 , —NHCOOR 4 , —NHCSOR 4 , —NHCONHR 4 , —NHCSNHR 4 , —NHSOR 4 , —NHSONHR 4 , —NHSO 2 R 4 , —NHSO 2 NHR 4 , and —SR 4 , wherein —R 4 is a C 1 -C 20 saturated or unsaturated, straight or branched alkyl group, optionally substituted with an A 1 group, wherein A 1 is selected from the group consisting of a halogen atom, or an aryl, heteroaryl, aryloxy or heteroaryloxy group, said aryl, heteroaryl, aryloxy or heteroaryloxy groups being optionally substituted with one or more C 1 -C 20 saturated or unsaturated, straight or branched alkyl or alkoxy group and/or halogen atom; Y − is selected from the group consisting of —COO − , PO 3 H − , —OPO 3 H − , tetrazolate-5-yl; with the proviso that when Z is —NHCOR 4 , Y is —COO − , then R 4 is C 20 alkyl; and with the proviso that when Z is —NHSO 2 R 4 , Y − is —COO − , then R 4 is not tolyl; their (R,S) racemic mixtures, their single R or S enantiomers, or their pharmaceutically acceptable salts.